Media coverage about Inovio Pharmaceuticals (NASDAQ:INO) has trended somewhat positive on Thursday, Accern reports. The research group scores the sentiment of press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Inovio Pharmaceuticals earned a coverage optimism score of 0.15 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 45.4459860745684 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

These are some of the news articles that may have impacted Accern’s scoring:

Shares of Inovio Pharmaceuticals (NASDAQ INO) opened at $4.46 on Thursday. Inovio Pharmaceuticals has a one year low of $4.20 and a one year high of $9.86.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.15). The business had revenue of $2.60 million during the quarter, compared to analyst estimates of $10.27 million. Inovio Pharmaceuticals had a negative net margin of 221.55% and a negative return on equity of 72.19%. Inovio Pharmaceuticals’s revenue was down 79.2% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.28) earnings per share. research analysts expect that Inovio Pharmaceuticals will post -1.12 earnings per share for the current fiscal year.

A number of brokerages recently commented on INO. BidaskClub downgraded shares of Inovio Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, October 27th. Citigroup began coverage on shares of Inovio Pharmaceuticals in a research report on Wednesday, September 6th. They set a “buy” rating and a $10.00 price objective on the stock. HC Wainwright set a $13.00 price objective on shares of Inovio Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, November 28th. Zacks Investment Research downgraded shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, November 13th. Finally, Maxim Group reaffirmed a “buy” rating and set a $12.00 price objective on shares of Inovio Pharmaceuticals in a research report on Tuesday, September 12th. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $19.16.

COPYRIGHT VIOLATION WARNING: This piece of content was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.watchlistnews.com/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-inovio-pharmaceuticals-ino-stock-price/1762742.html.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Insider Buying and Selling by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.